Clinical Trials Logo

Drug Toxicity clinical trials

View clinical trials related to Drug Toxicity.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06214468 Recruiting - Drug Toxicity Clinical Trials

Protective Effect of Nicotinamide Riboside Against Acetaminophen Toxicity

Start date: January 15, 2024
Phase: Phase 1
Study type: Interventional

Over-the-counter drugs like acetaminophen (e.g., Tylenol®) can be detrimental. In space, astronauts who have pain and constant discomfort use acetaminophen extensively. Investigators are studying the effects of acetaminophen under space-like conditions since acetaminophen might affect astronauts' health. Investigators also wish to see whether a dietary supplement can reduce some negative effects of acetaminophen. It is believed that acetaminophen promotes the productions of chemicals in the body that could be toxic. In this study, measurements of these chemicals in urine after ingestion of 1 tablet of acetaminophen and compare these measurements to when acetaminophen is taken at the same time as a dietary supplement. This study will also explore whether these products are more abundant when blood is placed under conditions that mimic space. Therefore, this study will collect blood from a few volunteers who took acetaminophen, and acetaminophen with the dietary supplement.

NCT ID: NCT05899751 Recruiting - Acute Kidney Injury Clinical Trials

Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate

Start date: April 1, 2022
Phase:
Study type: Observational

This retrospective observational study will evaluate high-dose methotrexate patterns of use, supportive care measures used during high-dose methotrexate chemotherapy, along with the incidence of delayed elimination of methotrexate, acute kidney injury and any associated impact of delayed elimination of methotrexate on future courses of chemotherapy and disease outcomes in adults and children with cancer. The study will compare current practice with existing guidelines and best practices to identify potential gaps in the management of high-dose methotrexate administration and delayed elimination of methotrexate. The study will identify variations in practice and outcomes in different study centers, countries, cancer types, patient age groups, by different methotrexate doses and infusion times and different supportive care measures used. The study will also document the proportion of high-dose methotrexate courses in which glucarpidase has been used and any toxicities attributable to the use of glucarpidase.

NCT ID: NCT05512169 Recruiting - Pediatric Cancer Clinical Trials

Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia

MPGx-INDALL
Start date: December 1, 2022
Phase:
Study type: Observational

A five-year prospective observational cohort study. The study is focused on observing the relation between static germline variants and therapeutic response in Indian children with acute lymphoblastic leukemia (ALL). The project is an International multicenter setup. This collaborative research project between Switzerland and India includes one main center in Geneva that has conceptualized, designed, received grants for the study and two investigating centers in India (Puducherry and New-Delhi) involved in study design, patient care and recruitment for this specific study. All the participants for the study will be recruited form these two centers in India, and no patient recruitment is planned at main center i.e. Geneva. The study will be conducted in two phases. The first aims to investigate genetic predisposition (static germline variants) to early chemotherapy treatment related toxicities (TRTs). The second aims to investigate somatic genetic markers associated with the efficacy of steroid treatment among patients undergoing the standardized IciCLe-ALL-14 treatment protocol. A total of 500 children with ALL will be recruited to investigate primary objective of the study i.e. TRT, and a subset of 250 patients will be included to investigate another research question i.e. response to steroid therapy.

NCT ID: NCT05329142 Recruiting - Drug Abuse Clinical Trials

ASSIST: A Surveillance Study of Illicit Substance Toxicity

ASSIST
Start date: August 19, 2022
Phase:
Study type: Observational

There is a drug-related death crisis in Scotland. This study aims to collaborate with Public Health Scotland in order to assess the feasibility of introducing a surveillance system to the Emergency Department to highlight illicit drug-related attendances. This will utilise both clinical data and toxiclogical analysis of anonymised samples. The data will inform of prevalence, trend data and utcome of ED patients attending with acute illict drug toxicity.

NCT ID: NCT05022797 Recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma

Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS

Start date: July 19, 2021
Phase: Phase 2
Study type: Interventional

Diffuse large B-cell lymphoma (DLBCL) is an aggressive subset of non-Hodgkin's lymphoma (NHL). Central nervous system (CNS) involvement in patients with NHL is a serious complication. The outcome of patients with CNS relapse is extremely poor, with a median survival of 4-6 months. One approach to reduce CNS relapse in high-risk patients is the use of systemic high-dose intravenous (iv) methotrexate (HMTX) chemotherapy. Currently available methods of MTX clearance, including dialysis-based methods, have shown limited efficacy. Glucarpidase hydrolyses MTX to inactive metabolites that are partially metabolised by the liver, thus providing an alternative route of limiting renal excretion. The administration of Glucarpidase could prevent MTX toxicity as a whole as well as the following consequences. The aim of this study is to analyse the prophylactic effect of 2,000 units of glucarpidase administered after 12 hours of HDMTX on MTX clearance and on the incidence and severity of MTX-related toxicity.

NCT ID: NCT04987801 Recruiting - Drug Toxicity Clinical Trials

Evaluation of Drug Overdose Poisoning Cases and Indications for ICU Admission

Start date: April 1, 2021
Phase:
Study type: Observational

1. Evaluation of drug overdose cases presented to Assiut university hospitals' adults and pediatric emergency departments (EDs) in one year period. 2. Evaluation the role of intensive care unit (ICU) admission in these cases and possible scoring system for common groups of drug overdose.

NCT ID: NCT04696081 Recruiting - Cancer Clinical Trials

Atrial Fibrillation in Active Cancer Patients

AFIB-CANCER
Start date: September 1, 2021
Phase:
Study type: Observational [Patient Registry]

Atrial fibrillation is a common complication of both cancer and anticancer drugs but the consequences of such events remain poorly known and are not adressed in both phase III oncological trials and cardiological guidelines. The objective of this study is to create a prospective multicenter international registry of adult patients with an active cancer and experiencing atrial fibrillation to study major cardiovascular events occurrence during a 1 year follow-up.

NCT ID: NCT04659343 Recruiting - Kidney Cancer Clinical Trials

TDM for Optimized Outcome in Patients With mRCC.

Start date: November 1, 2020
Phase:
Study type: Observational

The purpose of this observational study is to assess the role of plasma concentration monitoring of treatment drugs for patients with metastatic renal cell carcinoma (mRCC) in terms of efficacy and side effects. Furthermore, the investigators examines the role of anti-drug antibodies and receptor polymorphisms in CTLA-4 and PD-1 receptors in treatment failure among patients with mRCC treated with check point immunotherapy. Moreover, polymorphisms in the UGT1A1 gene will be correlated with the pazopanib treatment dose.

NCT ID: NCT04305145 Recruiting - Melanoma Stage IV Clinical Trials

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Start date: August 31, 2020
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin cancer. The main questions this study aims to answer are: - How many patients treated with infliximab experience steroid-free disease resolution after 7 weeks? - How many patients treated with steroids experience steroid-free disease resolution after 7 weeks?

NCT ID: NCT03885388 Recruiting - Drug Toxicity Clinical Trials

Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma (GTN) Patients With Score of 5-6

Start date: March 8, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

In this study, a prospective, multicenter randomized controlled study was conducted to compare the clinical efficacy and toxicity response of combination MTX+ACTD multi-course regimen in low-risk GTN patients with score 5-6 with standard MTX single-drug multi-course regimen.